Hydrochloric Acid

Hydrochloric Acid

SCHEMBL3845110

Cc1sc[n+](CC(=O)c2c(Cl)cccc2Cl)c1C.[Cl-]

nearest known ligand 0.53

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.53
FEN1 P39748 1/20 0.40
ALDH1A1 P00352 3/20 0.36
MITF O75030 1/20 0.34
RAD52 P43351 1/20 0.34
OPRM1 P35372 1/20 0.34
OPRD1 P41143 1/20 0.34
POLB P06746 3/20 0.33
MAPT P10636 3/20 0.33
TYK2 P29597 2/20 0.33
NPSR1 Q6W5P4 2/20 0.33
MEN1 O00255 3/20 0.32
PLA2G1B P04054 1/20 0.32
ATG4B Q9Y4P1 1/20 0.32
KDM4E B2RXH2 1/20 0.32
HPGD P15428 1/20 0.31
JAK2 O60674 1/20 0.31
CYP3A4 P08684 1/20 0.31
JAK1 P23458 1/20 0.31
MAPK1 P28482 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6535502 0.82 KMT2A (0.56) KMT2AALDH1A1OPRM1OPRD1POLB
Alagebrium SCHEMBL225618 0.78 KMT2A (0.69) KMT2AALDH1A1OPRM1OPRD1POLB
Hydrochloric Acid SCHEMBL3851286 0.77 KMT2A (0.50) KMT2AFEN1ALDH1A1MITFRAD52
Hydrochloric Acid SCHEMBL3850574 0.77 KMT2A (0.52) KMT2AALDH1A1OPRM1OPRD1POLB
Alagebrium SCHEMBL1820212 0.76 KMT2A (0.71) KMT2AALDH1A1OPRM1OPRD1POLB
SCHEMBL3846298 0.73 KMT2A (0.52) KMT2AALDH1A1MITFRAD52OPRM1
Bromide SCHEMBL8078699 0.72 KMT2A (0.58) KMT2AFEN1ALDH1A1POLBMEN1
SCHEMBL6535177 0.72 KMT2A (0.55) KMT2AALDH1A1OPRM1OPRD1MAPT
Bromide SCHEMBL3845051 0.72 KMT2A (0.61) KMT2AALDH1A1OPRM1OPRD1POLB
SCHEMBL6535467 0.72 KMT2A (0.74) KMT2AALDH1A1OPRM1OPRD1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2085086-A2 Method for treating congestive heart failure or diabetic nephropathy Synvista Therapeutics, Inc. (US) 2009-08-05 EP disclosed
US-20090124673-A1 Method for treating diabetic nephropathy SYNVISTA THERAPEUTICS , INC. (US) 2009-05-14 US disclosed
US-20090124674-A1 Method for treating congestive heart failure SYNVISTA THERAPEUTICS, INC. (US) 2009-05-14 US disclosed
US-7432254-B2 Method for treating glaucoma IC SYNVISTA THERAPEUTICS, INC. (US) 2008-10-07 US disclosed
EP-1353669-B1 METHOD FOR TREATING GLAUCOMA ALTEON INC (US) 2007-08-15 EP disclosed
US-7166625-B2 Method for treating fibrotic diseases and other indications ALTEON, INC. (US) 2007-01-23 US disclosed
EP-1305024-A4 METHOD FOR TREATING FIBROTIC DISEASES OR OTHER INDICATIONS IC ALTEON INC (US) 2006-03-22 EP disclosed
US-20040235837-A1 Method for treating fibrotic diseases or other indications IE SYNVISTA THERAPEUTICS, INC. 2004-11-25 US disclosed
EP-1305024-A1 METHOD FOR TREATING FIBROTIC DISEASES OR OTHER INDICATIONS IC Alteon, Inc. (US) 2003-05-02 EP disclosed
US-20020177586-A1 Method for treating fibrotic diseases or other indications ID SYNVISTA THERAPEUTICS, INC. 2002-11-28 US disclosed
US-20020160993-A1 Method for treating glaucoma IC SYNVISTA THERAPEUTICS, INC. 2002-10-31 US disclosed
US-20020068729-A1 Method for treating fibrotic diseases or other indications IC ALTEON, INC. 2002-06-06 US disclosed
WO-2002007725-A1 METHOD FOR TREATING FIBROTIC DISEASES OR OTHER INDICATIONS IC ALTEON, INC. (US) 2002-01-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235837-A1 Method for treating fibrotic diseases or other indications IE MMP1, COL1A1, COL2A1 KMT2A 4599/4885FEN1 1342/4885ALDH1A1 175/4885
US-20020160993-A1 Method for treating glaucoma IC CHAT, MYOC, GAP43 KMT2A 4535/4885FEN1 3380/4885ALDH1A1 366/4885
US-20020068729-A1 Method for treating fibrotic diseases or other indications IC MMP1, COL1A1, COL2A1 KMT2A 4545/4885FEN1 1857/4885ALDH1A1 204/4885
US-20090124673-A1 Method for treating diabetic nephropathy REN, SLC5A2, SLC5A1 KMT2A 4493/4885FEN1 2512/4885ALDH1A1 402/4885
US-20020177586-A1 Method for treating fibrotic diseases or other indications ID MMP1, COL1A1, COL2A1 KMT2A 4326/4885FEN1 1860/4885ALDH1A1 261/4885
US-20090124674-A1 Method for treating congestive heart failure TNNI3, TNNT2, FABP3 KMT2A 4520/4885FEN1 4043/4885ALDH1A1 448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.